225 related articles for article (PubMed ID: 36931805)
1. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
Dauvilliers Y; Lecendreux M; Lammers GJ; Franco P; Poluektov M; Caussé C; Lecomte I; Lecomte JM; Lehert P; Schwartz JC; Plazzi G
Lancet Neurol; 2023 Apr; 22(4):303-311. PubMed ID: 36931805
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
Szakacs Z; Dauvilliers Y; Mikhaylov V; Poverennova I; Krylov S; Jankovic S; Sonka K; Lehert P; Lecomte I; Lecomte JM; Schwartz JC;
Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985
[TBL] [Abstract][Full Text] [Related]
3. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
[TBL] [Abstract][Full Text] [Related]
4. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
Meskill GJ; Davis CW; Zarycranski D; Doliba M; Schwartz JC; Dayno JM
CNS Drugs; 2022 Jan; 36(1):61-69. PubMed ID: 34935103
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
Dauvilliers Y; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Thorpy MJ; Mignot E; Chandler P; Parvataneni R; Black J; Sterkel A; Chen D; Skobieranda F; Bogan RK
Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138
[TBL] [Abstract][Full Text] [Related]
7. Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials.
Watson NF; Davis CW; Zarycranski D; Vaughn B; Dayno JM; Dauvilliers Y; Schwartz JC
CNS Drugs; 2021 Dec; 35(12):1303-1315. PubMed ID: 34822113
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
[TBL] [Abstract][Full Text] [Related]
9. Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.
Dauvilliers Y; Šonka K; Bogan RK; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Chen A; Black J; Skobieranda F; Thorpy MJ
CNS Drugs; 2022 Jun; 36(6):633-647. PubMed ID: 35635687
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies.
Davis CW; Kallweit U; Schwartz JC; Krahn LE; Vaughn B; Thorpy MJ
Sleep Med; 2021 May; 81():210-217. PubMed ID: 33721598
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.
Bogan RK; Thorpy MJ; Dauvilliers Y; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Tang L; Skobieranda F; Šonka K
Sleep; 2021 Mar; 44(3):. PubMed ID: 33184650
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study.
Triller A; Pizza F; Lecendreux M; Lieberich L; Rezaei R; Pech de Laclause A; Vandi S; Plazzi G; Kallweit U
Sleep Med; 2023 Mar; 103():62-68. PubMed ID: 36758348
[TBL] [Abstract][Full Text] [Related]
13. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
[TBL] [Abstract][Full Text] [Related]
14. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
Dauvilliers Y; Shapiro C; Mayer G; Lammers GJ; Emsellem H; Plazzi G; Chen D; Carter LP; Lee L; Black J; Thorpy MJ
CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
[TBL] [Abstract][Full Text] [Related]
15. Pitolisant for treating patients with narcolepsy.
Li S; Yang J
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
[No Abstract] [Full Text] [Related]
16. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
Lecendreux M; Plazzi G; Dauvilliers Y; Rosen CL; Ruoff C; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
J Clin Sleep Med; 2022 Sep; 18(9):2217-2227. PubMed ID: 35689598
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy.
Setnik B; McDonnell M; Mills C; Scart-Grès C; Robert P; Dayno JM; Schwartz JC
Sleep; 2020 Apr; 43(4):. PubMed ID: 31626696
[TBL] [Abstract][Full Text] [Related]
18. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study.
Dauvilliers Y; Arnulf I; Szakacs Z; Leu-Semenescu S; Lecomte I; Scart-Gres C; Lecomte JM; Schwartz JC;
Sleep; 2019 Oct; 42(11):. PubMed ID: 31529094
[TBL] [Abstract][Full Text] [Related]
19. Pitolisant: A Review in Narcolepsy with or without Cataplexy.
Lamb YN
CNS Drugs; 2020 Feb; 34(2):207-218. PubMed ID: 31997137
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
Xyrem International Study Group
J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
